# Whitehawk Therapeutics, Inc.: overview WHWK · Nasdaq · CIK 1422142 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/whwk.md) · [Financials](/companies/whwk/financials.md) · [Filings](/companies/whwk/filings.md) · [Insiders](/companies/whwk/insiders.md) Latest reported revenue: [$0](/filings/0001193125-26-337933.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 6, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001193125-26-337933). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [7.2](/filings/0001193125-25-268895.md) | [7.2 d](/filings/0001193125-26-104158.md) | [7.1](/filings/0001193125-26-212075.md) | [0.0](/filings/0001193125-26-337933.md) | [0.0](/filings/0001193125-25-268895.md) | [0.0 d](/filings/0001193125-26-104158.md) | [0.0](/filings/0001193125-26-212075.md) | [0.0](/filings/0001193125-26-337933.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(186.0%)](/filings/0001193125-25-268895.md) | [(261.8%) d](/filings/0001193125-26-104158.md) | [(213.0%)](/filings/0001193125-26-212075.md) | not reported | not reported | not reported | not reported | not reported | | Net margin | % | [(174.0%)](/filings/0001193125-25-268895.md) | [(252.4%) d](/filings/0001193125-26-104158.md) | [1021.9%](/filings/0001193125-26-337933.md) | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(0.46)](/filings/0001193125-25-268895.md) | not reported | [1.83](/filings/0001193125-26-212075.md) | [(0.76)](/filings/0001193125-26-337933.md) | [(0.26)](/filings/0001193125-25-268895.md) | not reported | [(0.32)](/filings/0001193125-26-212075.md) | [(0.20)](/filings/0001193125-26-337933.md) | | Free cash flow | $m | [(15.9) d](/filings/0001193125-25-268895.md) | [(15.2) d](/filings/0001193125-26-104158.md) | [(12.4)](/filings/0001193125-26-212075.md) | [(53.0) d](/filings/0001193125-26-337933.md) | [(15.4) d](/filings/0001193125-25-268895.md) | [(17.2) d](/filings/0001193125-26-104158.md) | [(22.2)](/filings/0001193125-26-212075.md) | [(14.5) d](/filings/0001193125-26-337933.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [14.0](/filings/0001628280-24-010901.md) | [15.2](/filings/0001628280-24-010901.md) | [24.4](/filings/0001628280-25-015269.md) | [26.0](/filings/0001193125-26-104158.md) | [7.1](/filings/0001193125-26-104158.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(794.4%)](/filings/0001628280-23-009583.md) | [(411.9%)](/filings/0001628280-24-010901.md) | [(295.4%)](/filings/0001628280-25-015269.md) | [(259.6%)](/filings/0001193125-26-104158.md) | [(1601.1%)](/filings/0001193125-26-104158.md) | | Net margin | % | [(786.4%)](/filings/0001628280-23-009583.md) | [(397.7%)](/filings/0001628280-24-010901.md) | [(270.0%)](/filings/0001628280-25-015269.md) | [(245.1%)](/filings/0001193125-26-104158.md) | [(288.3%)](/filings/0001193125-26-104158.md) | | Diluted EPS | $ per share | [(12.41)](/filings/0001628280-23-009583.md) | [(2.69)](/filings/0001628280-24-010901.md) | [(2.44)](/filings/0001628280-25-015269.md) | [(2.36)](/filings/0001193125-26-104158.md) | [(0.33)](/filings/0001193125-26-104158.md) | | Free cash flow | $m | [(22.5)](/filings/0001628280-23-009583.md) | [(50.1)](/filings/0001628280-24-010901.md) | [(63.6)](/filings/0001628280-25-015269.md) | [(61.2)](/filings/0001193125-26-104158.md) | [(98.0)](/filings/0001193125-26-104158.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/whwk/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [Yu Fan](/funds/1668029.md) | 2026-06-30 | $22.3m | 4,861,314 | | Added +2,791,314 | | [ACUTA CAPITAL PARTNERS, LLC](/funds/1582844.md) | 2026-06-30 | $21.5m | 4,685,912 | | Added +1,275,510 | | [QVT Financial LP](/funds/1290162.md) | 2026-06-30 | $21.1m | 4,615,709 | | Unchanged | | [MONTANOVA CAPITAL, LLC](/funds/1569064.md) | 2026-06-30 | $19.7m | 4,300,000 | | Added +600,000 | | [ORBIMED ADVISORS LLC](/funds/1055951.md) | 2026-06-30 | $18.0m | 3,934,296 | | Reduced −231,704 | | [Avoro Capital Advisors LLC](/funds/1633313.md) | 2026-06-30 | $13.1m | 2,849,402 | | Unchanged | | [Siren, L.L.C.](/funds/2005245.md) | 2026-06-30 | $10.7m | 2,337,102 | | Added +255,102 | | [KVP Capital Advisors, LP](/funds/1858198.md) | 2026-06-30 | $9.9m | 2,165,997 | | Unchanged | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $8.8m | 1,922,828 | | Added +1,571,443 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $6.4m | 1,388,561 | | Added +72,791 | ## Recent filings [All 651 filings](/companies/whwk/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-09-10 | 17:02 ET | [8-K](/filings/0001193125-26-388010.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001193125-26-388010 | | 2026-08-06 | 16:03 ET | [10-Q](/filings/0001193125-26-337933.md) | Quarterly report, period 2026-06-30 | 0001193125-26-337933 | | 2026-08-06 | 10:08 ET | [8-K](/filings/0001193125-26-337069.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-337069 | | 2026-06-12 | 16:19 ET | [8-K](/filings/0001193125-26-269493.md) | 5.07 Shareholder vote results | 0001193125-26-269493 | | 2026-05-21 | 17:16 ET | [8-K](/filings/0001193125-26-234890.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-234890 | | 2026-05-18 | 19:03 ET | [SCHEDULE 13D/A](/filings/0000935836-26-000289.md) | Ownership report, active investor, amended | 0000935836-26-000289 | | 2026-05-14 | 20:04 ET | [SCHEDULE 13D/A](/filings/0000902664-26-002450.md) | Ownership report, active investor, amended | 0000902664-26-002450 | | 2026-05-13 | 08:08 ET | [8-K](/filings/0001193125-26-220656.md) | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-220656 | | 2026-05-07 | 16:25 ET | [10-Q](/filings/0001193125-26-212075.md) | Quarterly report, period 2026-03-31 | 0001193125-26-212075 | | 2026-05-07 | 09:12 ET | [8-K](/filings/0001193125-26-210615.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-210615 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-104158.md), filed Mar 12, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/ef9f4507-2fa5-4c40-91fa-a8cd9b8e1c44) ## About the filer - CIK: 1422142 - Tickers: WHWK - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:39 ET. No prices; not investment advice.